In patients with high-risk MM, post-transplant consolidation with the combination of an IMiD, PI, corticosteroid, and/or an anti-CD38 targeting monoclonal antibody may become more commonly utilized [50]. This evidence concerns the gene CD38 and Miyoshi myopathy.